DK2640391T3 - Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse - Google Patents
Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse Download PDFInfo
- Publication number
- DK2640391T3 DK2640391T3 DK11841746.8T DK11841746T DK2640391T3 DK 2640391 T3 DK2640391 T3 DK 2640391T3 DK 11841746 T DK11841746 T DK 11841746T DK 2640391 T3 DK2640391 T3 DK 2640391T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- compositions
- treating cognitive
- pyridazine derivatives
- weakness
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41397110P | 2010-11-15 | 2010-11-15 | |
PCT/US2011/060854 WO2012068161A1 (en) | 2010-11-15 | 2011-11-15 | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2640391T3 true DK2640391T3 (da) | 2016-02-15 |
Family
ID=46084380
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11841746.8T DK2640391T3 (da) | 2010-11-15 | 2011-11-15 | Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse |
DK15187794.1T DK3034079T3 (da) | 2010-11-15 | 2011-11-15 | Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15187794.1T DK3034079T3 (da) | 2010-11-15 | 2011-11-15 | Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse |
Country Status (12)
Country | Link |
---|---|
US (2) | US9145372B2 (da) |
EP (2) | EP3034079B1 (da) |
JP (1) | JP5916746B2 (da) |
CN (1) | CN103313712B (da) |
AU (1) | AU2011328993B2 (da) |
BR (1) | BR112013012062B1 (da) |
CA (1) | CA2818025A1 (da) |
DK (2) | DK2640391T3 (da) |
EA (1) | EA027840B1 (da) |
MX (1) | MX346185B (da) |
NO (1) | NO3034079T3 (da) |
WO (1) | WO2012068161A1 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO3034079T3 (da) | 2010-11-15 | 2018-06-09 | ||
EP2642919A4 (en) * | 2010-11-26 | 2014-10-08 | Brigham & Womens Hospital | METHOD FOR EVALUATING REPETITIVE HEAD INJURY LESIONS USING TWO-DIMENSIONAL MAGNETIC RESONANCE SPECTROSCOPY |
EP2897963A4 (en) | 2012-09-21 | 2016-03-30 | Uwm Res Foundation Inc | NOVEL GABAA AGONISTS AND METHODS OF USING THEM TO CONTROL BRONCHIC HYPER-REACTION AND INFLAMMATION DURING ASTHMA |
WO2014078377A1 (en) * | 2012-11-14 | 2014-05-22 | Agenebio, Inc. | Methods and compositions for treating schizophrenia |
MX2016007808A (es) | 2013-12-20 | 2016-09-07 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo. |
CN113264939A (zh) | 2015-06-19 | 2021-08-17 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
TWI697485B (zh) * | 2015-07-21 | 2020-07-01 | 日商捷恩智股份有限公司 | 含唑啉環的化合物、含有其的電子輸送/注入層用材料、使用其的有機電致發光元件、顯示裝置及照明裝置 |
US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
WO2019246300A1 (en) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
CN113840569A (zh) | 2019-03-19 | 2021-12-24 | 剑桥认知有限公司 | 诊断精神病症和推荐用于精神病症的治疗的方法和用途 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
ES413944A1 (es) | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
CA2000786C (en) | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
ATE94384T1 (de) | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
DK0402644T3 (da) | 1989-05-19 | 1996-01-02 | Hoechst Roussel Pharma | N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter |
US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
DE69131268T2 (de) | 1990-09-21 | 1999-12-30 | Rohm & Haas | Dihydropyridazinone und Pyridazinone als Fungizide |
US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
EP0586551A1 (en) | 1991-05-24 | 1994-03-16 | E.I. Du Pont De Nemours And Company | Arthropodicidal anilides |
US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
TW201311B (da) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
KR100330942B1 (ko) | 1994-03-02 | 2002-11-16 | 악조 노벨 엔.브이. | 설하또는협측투여용약학조성물 |
US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
AU1041599A (en) | 1997-11-13 | 1999-06-07 | Jose Luis Castro Pineiro | Therapeutic uses of triazolo-pyridazine derivatives |
US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
EP1129094A2 (en) | 1998-11-12 | 2001-09-05 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
ATE277011T1 (de) | 1999-03-03 | 2004-10-15 | Eisai Co Ltd | Flouride von 4-substituierten piperidin-derivaten |
GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
KR20030076717A (ko) | 2001-03-01 | 2003-09-26 | 화이자 프로덕츠 인크. | 인지 장애의 치료를 위한 니코틴 수용체 부분 아고니스트,에스트로겐, 선택적 에스트로겐 조정자 또는 비타민 e와함께, gabaa 역아고니스트의 용도 |
US20050071088A1 (en) | 2001-08-13 | 2005-03-31 | Landfield Philip W | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
JP2005518411A (ja) | 2002-01-16 | 2005-06-23 | エンド ファーマシューティカルズ インコーポレーテッド | 中枢神経系の障害を治療する製薬組成物及び方法 |
GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
CA2495285A1 (en) * | 2002-08-13 | 2004-02-19 | Merck Sharp & Dohme Limited | Phenylpyridazine derivatives as ligands for gaba receptors |
US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
GEP20094759B (en) | 2002-10-24 | 2009-08-25 | Merz Pharma Gmbh & Co Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
JP2006510357A (ja) | 2002-11-22 | 2006-03-30 | ザ ジョーンズ ホプキンズ ユニバーシティ | 認識障害の処置のための標的 |
JP2007509165A (ja) | 2003-10-22 | 2007-04-12 | メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン | アミロイドパシーにおいて、フィブリロジェニックAβペプチドの沈着を改変するために、1−アミノシクロヘキサン誘導体を使用する方法 |
AU2005286672B2 (en) | 2004-09-23 | 2009-03-12 | Merz Pharma Gmbh & Co. Kgaa | Memantine for the treatment of childhood behavioral disorders |
JP5117192B2 (ja) | 2004-10-12 | 2013-01-09 | エフ.ホフマン−ラ ロシュ アーゲー | 置換ベンゾジアゼピン誘導体 |
RU2007112940A (ru) | 2004-10-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные имидазобензодиазепина |
US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
AU2006276998A1 (en) | 2005-05-16 | 2007-02-15 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
WO2007019312A2 (en) | 2005-08-03 | 2007-02-15 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
CA2730148C (en) | 2008-08-01 | 2018-04-03 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
US20110136762A1 (en) * | 2008-09-24 | 2011-06-09 | E.I. Du Pont De Nemours And Company | Fungicidal pyridazines |
MX342439B (es) | 2008-09-25 | 2016-09-29 | Vive Nano Inc * | Metodos para producir nanoparticulas polimericas y formulaciones de ingredientes activos. |
US8344028B2 (en) | 2009-04-17 | 2013-01-01 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as GABAB receptor ligands |
JP2013516497A (ja) | 2010-01-11 | 2013-05-13 | ミスリィディオン,インク. | 認知増強のための化合物と組成物、製造方法、および治療方法 |
AU2011329068A1 (en) | 2010-11-15 | 2013-06-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment |
NO3034079T3 (da) | 2010-11-15 | 2018-06-09 | ||
WO2012161133A1 (ja) * | 2011-05-20 | 2012-11-29 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
MX2015003035A (es) | 2012-09-10 | 2015-09-21 | Ophirex Inc | Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual. |
MX2016007808A (es) | 2013-12-20 | 2016-09-07 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo. |
-
2011
- 2011-11-15 NO NO15187794A patent/NO3034079T3/no unknown
- 2011-11-15 EP EP15187794.1A patent/EP3034079B1/en active Active
- 2011-11-15 JP JP2013539003A patent/JP5916746B2/ja active Active
- 2011-11-15 US US13/885,569 patent/US9145372B2/en not_active Expired - Fee Related
- 2011-11-15 CA CA2818025A patent/CA2818025A1/en not_active Abandoned
- 2011-11-15 MX MX2013005442A patent/MX346185B/es active IP Right Grant
- 2011-11-15 DK DK11841746.8T patent/DK2640391T3/da active
- 2011-11-15 DK DK15187794.1T patent/DK3034079T3/da active
- 2011-11-15 EA EA201390712A patent/EA027840B1/ru not_active IP Right Cessation
- 2011-11-15 EP EP11841746.8A patent/EP2640391B1/en active Active
- 2011-11-15 AU AU2011328993A patent/AU2011328993B2/en not_active Ceased
- 2011-11-15 CN CN201180063261.2A patent/CN103313712B/zh not_active Expired - Fee Related
- 2011-11-15 BR BR112013012062-2A patent/BR112013012062B1/pt not_active IP Right Cessation
- 2011-11-15 WO PCT/US2011/060854 patent/WO2012068161A1/en active Application Filing
-
2015
- 2015-09-18 US US14/858,959 patent/US9801879B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20160008357A1 (en) | 2016-01-14 |
EP3034079B1 (en) | 2018-01-10 |
AU2011328993B2 (en) | 2017-03-02 |
CN103313712B (zh) | 2016-10-26 |
US9145372B2 (en) | 2015-09-29 |
US20130237545A1 (en) | 2013-09-12 |
US9801879B2 (en) | 2017-10-31 |
WO2012068161A1 (en) | 2012-05-24 |
BR112013012062A2 (pt) | 2016-08-16 |
JP5916746B2 (ja) | 2016-05-11 |
CA2818025A1 (en) | 2012-05-24 |
EA027840B1 (ru) | 2017-09-29 |
NO3034079T3 (da) | 2018-06-09 |
EA201390712A1 (ru) | 2013-11-29 |
BR112013012062B1 (pt) | 2020-06-02 |
EP2640391A4 (en) | 2014-05-07 |
MX2013005442A (es) | 2013-10-03 |
JP2013542267A (ja) | 2013-11-21 |
DK3034079T3 (da) | 2018-02-05 |
AU2011328993A1 (en) | 2013-06-06 |
EP2640391B1 (en) | 2015-11-11 |
CN103313712A (zh) | 2013-09-18 |
EP3034079A1 (en) | 2016-06-22 |
EP2640391A1 (en) | 2013-09-25 |
MX346185B (es) | 2017-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2640391T3 (da) | Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse | |
DK3202460T3 (da) | Arylmethoxy-isoindolinderivater og sammensætninger omfattende og fremgangsmåder til anvendelser af samme | |
DK3064585T3 (da) | Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation | |
DK2247582T3 (da) | Vandfri, krystallinsk form af dimethoxydocetaxel og fremgangsmåder til fremstilling heraf | |
DK2585437T3 (da) | Thioacetatforbindelser, sammensætninger og fremgangsmåder til anvendelse heraf | |
DK3569256T3 (da) | Stabiliserede fibronectin-domænesammensætninger, fremgangsmåder og anvendelser | |
DK3597749T3 (da) | Fremgangsmåder og sammensætninger til rna-dirigeret mål-dna-modificering og til rna-dirigeret modulering af transkription | |
DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
DK2699553T3 (da) | Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed | |
DK2688557T3 (da) | Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed | |
DK2776567T3 (da) | Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. | |
DK2890780T3 (da) | Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand | |
DK3127540T3 (da) | Visse amino-pyrimidiner, sammensætninger deraf, og fremgangsmåder til deres anvendelse | |
DK3329775T3 (da) | Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser | |
DK2583586T4 (da) | Indretning til registrering af kollisioner og tilsvarende fremgangsmåde | |
DK3795573T3 (da) | Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf | |
DK2498771T3 (da) | Anvendelse af bethanechol til behandling af xerostomi | |
DK2489670T3 (da) | Fremgangsmåde til fremstilling af aminosyre-chelatforbindelser, aminosyre-chelatforbindelser og anvendelse af aminosyre-chelatforbindelser | |
DK2987507T3 (da) | Fremgangsmåder til behandling af degenerative knogletilstande | |
DK2558105T3 (da) | Bardoxolonmethyl til behandling af fedme | |
DK3192520T3 (da) | Terapeutiske midler til reducering af niveauerne af parathyreoideahormon | |
DK3260118T3 (da) | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion | |
DK2598500T3 (da) | Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen | |
DK2446246T3 (da) | Indretning og fremgangsmåde til udvælgelse af partikler | |
DK3284820T3 (da) | Fremgangsmåde til behandling af pyropheophytin-holdige sammensætninger |